Drug Profile
Research programme: neurodegenerative disorders therapeutics - Alnylam Pharmaceuticals/Medtronic
Alternative Names: ALN-HTT; RNAi therapeutic drug-device combination for Huntington's disease - Alnylam/Medtronic; RNAi therapeutic programme - Alnylam Pharmaceuticals/Medtronic; RNAi therapeutics - Alnylam Pharmaceuticals/MedtronicLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Medtronic
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease; Neurodegenerative disorders
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Intrastriatal, Infusion)
- 19 Nov 2021 Preclinical development is ongoing in Huntington's-disease in USA (Intrastriatal, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intrastriatal, Infusion)